Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | -0.00 |
| FCF Yield | 8,863.06% | 6,989.68% | 1,668.14% | 4,084.60% |
| EV / EBITDA | 7.66 | 11.67 | 9.01 | 16.12 |
| Quality | ||||
| ROIC | 3.69% | 4.23% | 4.05% | 1.55% |
| Gross Margin | 66.00% | 65.78% | 65.53% | 60.15% |
| Cash Conversion Ratio | 2.88 | 2.98 | 0.80 | 58.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.25% | 1.82% | 1.28% | 1.52% |
| Free Cash Flow Growth | 68.48% | 109.92% | -58.29% | -22.90% |
| Safety | ||||
| Net Debt / EBITDA | 7.64 | 11.66 | 8.99 | 16.08 |
| Interest Coverage | 8.01 | 8.49 | 7.13 | 5.10 |
| Efficiency | ||||
| Inventory Turnover | 1.51 | 1.53 | 1.45 | 1.92 |
| Cash Conversion Cycle | 74.50 | 53.12 | 86.06 | 62.05 |